AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?

When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one sits to the edge varies far more than the yields suggest.